Home › Therapeutic areas › Oncology › Lymphoma
Lymphoma (16 companies)
Companies with an active program in Lymphoma.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Programs |
|---|---|---|---|---|---|
| ADCT | ADC Therapeutics | Oncology | 3 | Approved | 5 |
| ALDX | Aldeyra Therapeutics | DermatologyOncology+1 Rare | 1 | NDA Submitted | 7 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | 10 |
| ARVN | Arvinas | NeurologyOncology Rare | 1 | Approved | 12 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 2 | Approved | 12 |
| CRBU | Caribou Biosciences | Oncology | 3 | Phase 1 | 4 |
| CLRB | Cellectar Biosciences | Oncology | 1 | Phase 2 | 6 |
| CRVS | Corvus Pharmaceuticals | DermatologyOncology | 1 | Phase 3 | 4 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | 16 |
| IMNM | Immunome | Oncology Rare | 1 | NDA Submitted | 9 |
| LEGN | Legend Biotech | Oncology Rare | 1 | Approved | 8 |
| MRKR | Marker Therapeutics | Oncology | 1 | Phase 1 | 4 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 1 | Phase 3 | 11 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 5 | Phase 3 | 16 |
| SANA | Sana Biotechnology | MetabolicOncology | 1 | Phase 1 | 4 |
| XNCR | Xencor | HematologyImmunology+4 Rare | 2 | Approved | 36 |
No companies match.